Feasibility of high-dose chemotherapy (HDCT) with doble autologous stem cell transplantation (ASCT) for Ewing and soft tissue sarcomas

21501 Background: To improve long-term outcome of metastatic sarcoma patients (pts), we started a tandem ASCT program in compassionate use. Its feasibility is analyzed. Methods: From January/2004 to April/2007, 11 pts (8 males, age 29 [19 - 51] years) were included: 7 Ewing, 2 rabdomyosarcoma, 1 sinovial and 1 leiomyosarcoma. Patients included in the program were those with CR or PR after conventional chemotherapy (CT). Median treatment lines before transplant was 1 (1–3). Conditioning regimen for both ASCTs was ICE protocol (HDCT) (ifosfamide 2,500 mg/m2 iv × 4 d, carboplatin 360 mg/m2 iv × 4 d., etoposide 310 mg/m2 iv × 4 d.). A minimum number of 4 × 106 CD34+/kg cels were collected. Results: 5 pts were in CR, 5 in PR just before ASCT. 1 pt that achieved a PR after CT, presented with an early progression just before the first ASCT. All pts underwent the first procedure. Post-transplant toxicity: grade (G) 4 neutropenia: (11d [7d-14d]), G4 thrombocytopenia: (7.7d [4–12]), G 3–4 gastrointestinal (GI) toxi...